Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Magle Chemoswed Q3 - Record high sales bolstered by merger

Magle Chemoswed Holding

Redeye provides a research update following the Q3 report recently published by Magle. Following the merger and acquisitions of pK Chemicals and Amniotics, we believe that Magle is poised to generate long-term shareholder value. Furthermore, the company reported record high sales figures at SEK64.6, a 78% y/y growth, with an impressive 32% EBITDA margin. We reiterate our fair value range (SEK30 – SEK70) with a base case valuation of SEK50.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Magle Chemoswed Q3 - Record high sales bolstered by merger

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.